Literature DB >> 2473806

Molecular analysis of beta zero-thalassemia intermedia in Sardinia.

R Galanello1, E Dessi, M A Melis, M Addis, M A Sanna, C Rosatelli, F Argiolu, N Giagu, M P Turco, E Cacace.   

Abstract

In this study we have carried out alpha- and beta-globin gene analysis and defined the beta-globin gene polymorphisms in a group of patients with thalassemia intermedia of Sardinian descent. A group of patients (109) with thalassemia major of the same origin served as control. Characterization of the beta-thalassemia mutation showed either a frameshift mutation at codon 6 or a codon 39 nonsense mutation. We found that homozygotes for the frameshift mutation at codon 6 or compound heterozygotes for this mutation and for the codon 39 nonsense mutation develop thalassemia intermedia more frequently than thalassemia major. The frameshift mutation at codon 6 was associated with haplotype IX that contains the C-T change at position -158 5' to the G gamma globin gene implicated in high gamma chain production and thus the mild phenotype. In patients' homozygotes for codon 39 nonsense mutation, those with thalassemia intermedia more frequently had the two-gene deletion form of alpha-thalassemia, or functional loss of the alpha 2 gene as compared with those with thalassemia major. In a few siblings with thalassemia major and intermedia, the thalassemia intermedia syndrome correlated with the presence of the -alpha/-alpha genotype. No cause for the mild phenotype was detected in the majority of patients who had not inherited either haplotype IX or alpha-thalassemia.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2473806

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  Control of fetal hemoglobin: new insights emerging from genomics and clinical implications.

Authors:  Swee Lay Thein; Stephan Menzel; Mark Lathrop; Chad Garner
Journal:  Hum Mol Genet       Date:  2009-10-15       Impact factor: 6.150

2.  Epistatic interactions between genetic disorders of hemoglobin can explain why the sickle-cell gene is uncommon in the Mediterranean.

Authors:  Bridget S Penman; Oliver G Pybus; David J Weatherall; Sunetra Gupta
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-01       Impact factor: 11.205

3.  1993 William Allan award address.

Authors:  A Cao
Journal:  Am J Hum Genet       Date:  1994-03       Impact factor: 11.025

4.  Phenotypic effect of α-globin gene numbers on Indian sickle β-thalassemia patients.

Authors:  Sanjay Kumar Pandey; Sweta Pandey; Ravi Ranjan; Vineet Shah; Rahasya Mani Mishra; Monica Sharma; Renu Saxena
Journal:  J Clin Lab Anal       Date:  2014-01-06       Impact factor: 2.352

Review 5.  Carrier screening and genetic counselling in beta-thalassemia.

Authors:  Antonio Cao
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 6.  Beta-thalassaemia prototype of a single gene disorder with multiple phenotypes.

Authors:  Swee Lay Thein
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

7.  From genotype to phenotype: genetics and medical practice in the new millennium.

Authors:  D Weatherall
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-12-29       Impact factor: 6.237

8.  Amelioration of Sardinian beta0 thalassemia by genetic modifiers.

Authors:  Renzo Galanello; Serena Sanna; Lucia Perseu; Maria Carla Sollaino; Stefania Satta; Maria Eliana Lai; Susanna Barella; Manuela Uda; Gianluca Usala; Goncalo R Abecasis; Antonio Cao
Journal:  Blood       Date:  2009-08-20       Impact factor: 22.113

Review 9.  The prevention of thalassemia.

Authors:  Antonio Cao; Yuet Wai Kan
Journal:  Cold Spring Harb Perspect Med       Date:  2013-02-01       Impact factor: 6.915

10.  Thalassemia intermedia: compound heterozygous beta zero/beta(+)-thalassemia and co-inherited heterozygous alpha(+)-thalassemia.

Authors:  A E Kulozik; E Kohne; E Kleihauer
Journal:  Ann Hematol       Date:  1993-01       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.